SYSTEMIC SCLEROSIS
Clinical trials for SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat scleroderma in landmark trial
Disease control Not yet recruitingThis study tests whether a one-time infusion of specially engineered immune cells (CAR T cells) can improve lung function and skin hardening better than current treatments for people with active systemic sclerosis, a rare autoimmune disease. About 92 adults with lung involvement …
Matched conditions: SYSTEMIC SCLEROSIS
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Off-the-Shelf CAR-Ts take on lupus and more
Disease control Not yet recruitingThis early-phase trial tests a single dose of universal (off-the-shelf) CAR-T cells in 30 adults with active autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's. The treatment targets CD19 and BCMA on immune cells to reset the faulty immune system. The…
Matched conditions: SYSTEMIC SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Continued anifrolumab treatment studied for lupus and related diseases
Disease control Not yet recruitingThis study offers continued access to anifrolumab (Saphnelo) for people with systemic lupus erythematosus, systemic sclerosis, or myopathies who completed a prior anifrolumab trial and are still benefiting from the drug. Participants receive the same treatment as before, while re…
Matched conditions: SYSTEMIC SCLEROSIS
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…
Matched conditions: SYSTEMIC SCLEROSIS
Phase: PHASE1 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug HBM7020 tested in humans for first time against autoimmune diseases
Disease control Not yet recruitingThis first-in-human study tests the safety of a new drug called HBM7020. It will first be given to healthy volunteers at low doses, then to people with moderate to severe autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see …
Matched conditions: SYSTEMIC SCLEROSIS
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental CAR-T injection aims to tame autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…
Matched conditions: SYSTEMIC SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune retraining: could CAR-Treg cells tame autoimmune disease?
Disease control Not yet recruitingThis early-phase study tests a new treatment called BEN301, which uses specially engineered immune cells (CAR-Tregs) to calm overactive immune responses in people with autoimmune diseases like scleroderma, rheumatoid arthritis, lupus, and inflammatory muscle disease. The trial wi…
Matched conditions: SYSTEMIC SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
MRNA technology takes on autoimmune diseases in new trial
Disease control Not yet recruitingThis early-phase study tests a new mRNA therapy that targets CD19, a protein on immune cells, to treat autoimmune diseases like lupus and immune anemia. The treatment uses lipid nanoparticles to deliver mRNA that helps the body clear harmful B cells. About 47 participants aged 14…
Matched conditions: SYSTEMIC SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Not yet recruitingThis early study tests a new treatment called CD19 UCAR-T cells for people with autoimmune diseases like lupus, vasculitis, and Sjögren's syndrome. The therapy uses modified immune cells to target and calm the overactive immune system. The main goals are to check safety and see i…
Matched conditions: SYSTEMIC SCLEROSIS
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Immune system reset: CAR T-Cells take on autoimmune diseases
Disease control Not yet recruitingThis study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …
Matched conditions: SYSTEMIC SCLEROSIS
Phase: PHASE1, PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC
-
Finger injections aim to loosen stiff hands in scleroderma
Symptom relief Not yet recruitingThis early-phase trial investigates whether monthly injections of hyaluronidase into the fingers can improve stiffness and hand function in people with systemic sclerosis who have sclerodactyly (tight, thickened skin on the fingers). The study enrolls 10 adults aged 18 to 60 and …
Matched conditions: SYSTEMIC SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Immune clues in the blood may foretell heart trouble
Knowledge-focused Not yet recruitingThis study is building a biobank of blood samples and imaging data from 300 people with suspected inflammatory heart or autoimmune rheumatic diseases. Researchers aim to identify immune biomarkers that could predict major heart events like heart failure, stroke, or atrial fibrill…
Matched conditions: SYSTEMIC SCLEROSIS
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Blood particles may reveal hidden clues to scleroderma complications
Knowledge-focused Not yet recruitingThis study looks at how tiny particles called extracellular vesicles travel through the bloodstream in people with systemic sclerosis, an autoimmune disease that affects blood vessels and organs. Researchers will take blood samples from different points in the circulation to see …
Matched conditions: SYSTEMIC SCLEROSIS
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Blood markers may spot Kids' lung disease earlier
Knowledge-focused Not yet recruitingThis study looks at whether two substances in the blood, IL-6 and MMP-7, can help doctors diagnose and predict the course of a rare lung disease in children. Researchers will measure these markers in 60 children with immune-mediated interstitial lung disease and compare them to h…
Matched conditions: SYSTEMIC SCLEROSIS
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Scleroderma patients to decide: infographic vs. plain language for research results
Knowledge-focused Not yet recruitingThis study aims to find the best way to share research results with people who have scleroderma, a rare autoimmune disease. About 128 participants will be randomly assigned to receive either an infographic or a plain-language summary of a study. They will then rate how complete, …
Matched conditions: SYSTEMIC SCLEROSIS
Phase: NA • Sponsor: Lady Davis Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Simple blood test may spot heart risk in scleroderma patients
Knowledge-focused Not yet recruitingThis study looks at whether a substance in the blood called catestatin is linked to heart and blood vessel problems in people with systemic sclerosis (scleroderma). Researchers will measure catestatin levels in 70 patients and compare them to healthy people. The goal is to see if…
Matched conditions: SYSTEMIC SCLEROSIS
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Scleroderma Patients' sleep troubles under the microscope
Knowledge-focused Not yet recruitingThis study will use an overnight sleep test (polysomnography) to measure breathing problems during sleep in 30 adults with systemic sclerosis (scleroderma). The goal is to find out how common sleep-disordered breathing is in this group. No treatment is given—this is purely an obs…
Matched conditions: SYSTEMIC SCLEROSIS
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:11 UTC
-
Can a simple ultrasound reveal hidden gut damage in scleroderma?
Knowledge-focused Not yet recruitingThis study will use Doppler ultrasound to measure blood flow in the gut arteries of 74 people with systemic sclerosis (scleroderma) and compare them to healthy volunteers. The goal is to see if changes in blood flow relate to digestive symptoms and other organ problems. This is a…
Matched conditions: SYSTEMIC SCLEROSIS
Sponsor: Esraa Moustafa Mohammed • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:33 UTC
-
New study aims to predict best treatments for rheumatoid diseases using AI and health data
Knowledge-focused Not yet recruitingThis study will collect health information, samples, and data from 100 people in Luxembourg (800 total across Europe) who have rheumatoid diseases and are starting or changing treatment. Researchers hope to find patterns that can predict which treatments work best for each person…
Matched conditions: SYSTEMIC SCLEROSIS
Sponsor: Luxembourg Institute of Health • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:31 UTC